Compare Hormel Foods Corp (HRL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hormel Foods Corp vs Novavax Inc — how do they compare? Hormel Foods Corp trades at $19.25 (market cap $10.69B), while Novavax Inc trades at $12.84 (market cap $1.82B). The key difference: Hormel Foods Corp is far larger — about 5.9× Novavax Inc's market cap, and Hormel Foods Corp pays a 6.02% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hormel Foods Corp for 99 Days and Novavax Inc for 59 Days on average.
| HRL | NVAX | |
|---|---|---|
Market Cap | $10.69B | $1.82B |
Volume | 10,041,387 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $26.50 | $12.56 |
52-Week Low | $19.42 | $6.22 |
Typical Hold Time | 99 Days | 59 Days |
Enterprise Value | $12.67B | $1.39B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hormel Foods (HRL) trades at $19.23, down 1.64% on the day, with a bearish technical outlook despite recent earnings beats. The company maintains a P/E of 31.32 and P/S of 0.88, with net income margin at 2.82%. Recent $1.06B Brakebush acquisition aims to expand foodservice presence, while dividend consistency remains a key investor focus with 60 consecutive years of increases.
Outlook remains cautious with mixed analyst sentiment (20% buy, 57% hold) and a $24.25 consensus target offering 26% upside. Risks include margin pressure, acquisition integration challenges, and declining dividend growth rates. The stock presents value potential but requires monitoring of operational execution amid competitive pressures.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
